Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, with a notable performance difference between domestic and overseas markets [1][2]. Group 1: Financial Performance - In H1 2025, the company achieved revenue of 2.185 billion (yoy -1.18%) and a net profit attributable to shareholders of 771 million (yoy -14.62%) [1]. - Q2 2025 revenue was 1.060 billion (yoy -10.88%), with a net profit of 334 million (yoy -30.06%) [1]. - The company's comprehensive gross margin for H1 2025 was 68.64% (yoy -4.14 percentage points) [3]. Group 2: Revenue Breakdown - In H1 2025, reagent revenue was 1.521 billion (yoy -4.40%), while instrument revenue was 660 million (yoy +7.37%) [2]. - Domestic revenue was 1.229 billion (yoy -12.81%), with domestic instrument business revenue increasing by 18.18% [2]. - Overseas revenue reached 952 million (yoy +19.57%), with reagent business revenue growing by 36.86% [2]. Group 3: Product Development and Market Position - The company has expanded its product matrix, with the X series flagship models receiving domestic product registration [3]. - The number of small molecule double antibody sandwich method reagents has increased to 14, covering various medical fields [3]. - The company’s R&D expense ratio was 10.86% (yoy +1.62%) [3]. Group 4: Future Projections - Revenue projections for 2025-2027 are 4.858 billion, 5.496 billion, and 6.348 billion, with growth rates of 7.12%, 13.12%, and 15.51% respectively [3]. - Net profit forecasts for the same period are 1.832 billion, 2.065 billion, and 2.385 billion, with growth rates of 0.17%, 12.77%, and 15.48% respectively [3]. - The current price-to-earnings ratios are projected at 25x, 22x, and 19x for 2025, 2026, and 2027 [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to face domestic pressure in the short term, but the production line is anticipated to drive reagent volume growth [5] - Revenue forecasts for 2025-2027 are projected at 48.58 billion, 54.96 billion, and 63.48 billion RMB, with year-on-year growth rates of 7.12%, 13.12%, and 15.51% respectively [6] - The net profit attributable to the parent company for the same period is expected to be 18.32 billion, 20.65 billion, and 23.85 billion RMB, with growth rates of 0.17%, 12.77%, and 15.48% respectively [6] - The current stock price corresponds to a price-to-earnings ratio (PE) of 25x, 22x, and 19x for the years 2025, 2026, and 2027 [6] Financial Performance Summary - In the first half of 2025, the company achieved revenue of 21.85 billion RMB (down 1.18% year-on-year) and a net profit of 7.71 billion RMB (down 14.62% year-on-year) [8] - The company's reagent revenue was 15.21 billion RMB (down 4.40% year-on-year), while instrument revenue was 6.60 billion RMB (up 7.37% year-on-year) [8] - Domestic revenue was 12.29 billion RMB (down 12.81% year-on-year), with domestic instrument business revenue increasing by 18.18% [8] - Overseas revenue reached 9.52 billion RMB (up 19.57% year-on-year), with reagent business revenue growing by 36.86% [8] - The overall gross margin for the first half of 2025 was 68.64% (down 4.14 percentage points year-on-year) [8] - The company’s R&D expense ratio was 10.86% (up 1.62 percentage points year-on-year) [8] Revenue and Profit Forecasts - Revenue forecasts for 2025-2027 are 48.58 billion, 54.96 billion, and 63.48 billion RMB, with corresponding year-on-year growth rates of 7.12%, 13.12%, and 15.51% [6] - The net profit attributable to the parent company is projected to be 18.32 billion, 20.65 billion, and 23.85 billion RMB for 2025, 2026, and 2027, with growth rates of 0.17%, 12.77%, and 15.48% respectively [6] - The earnings per share (EPS) for 2025 is expected to be 2.33 RMB, with a projected increase to 3.04 RMB by 2027 [9]

Financial Performance - In 2024, the company achieved operating revenue of CNY 4.535 billion, a year-on-year increase of 15.41% [2] - The net profit attributable to shareholders was CNY 1.828 billion, growing by 10.57% compared to the previous year [2] - In Q1 2025, the operating revenue reached CNY 1.125 billion, reflecting a year-on-year growth of 10.12% [2] Domestic Market Insights - In 2024, the company generated CNY 2.843 billion in main business revenue domestically, marking a 9% increase [3] - A total of 1,641 automated chemiluminescence analyzers were installed in the domestic market, with large machines accounting for 75% of installations [3] - In Q1 2025, 412 automated chemiluminescence analyzers were installed, with large machines making up 76% of the total [3] International Market Performance - In 2024, the company recorded CNY 1.684 billion in main business revenue from overseas, a 28% increase [4] - The overseas reagent business revenue grew by 26% in the same year [4] - In Q1 2025, overseas main business revenue continued to grow by 27%, with reagent business revenue increasing by 40% [4] Strategic Responses to Market Changes - The company plans to embrace domestic procurement and medical insurance payment reforms actively, focusing on high-quality and cost-effective products [6] - Continuous technological innovation is emphasized to enhance product competitiveness and meet clinical demands for sensitivity and accuracy [7] - The company aims to maintain a strong presence in both domestic and international markets through a global strategy and localized marketing efforts [9] Future Outlook - The company expects to enhance its market competitiveness by leveraging its four major technology platforms and integrating instruments with reagents [8] - The overseas business is projected to maintain steady growth, with an increasing share of total revenue [10]